在收购 Spyre 之前,Aeg...查看全文
美股滚雪球2023-06-25 15:05
$Aeglea生物制药(AGLE)$ 宣布以换股交易的方式收购Spyre Therapeucs。通过收购,Aeglea(AGLE)获得了SPY001和SPY002,这两种炎症性肠病候选抗体预计将于2024年进入临床。
Aeglea(AGLE)还就PIPE投资达成协议,筹集2.1亿美元,其中投资者将获得721452股a系列优先股(721452000股,转换为普通...查看全文
产业链观察2022-08-19 20:19
药闻▶2022年8月18日,临床阶段的生物技术公司$Aeglea生物制药(AGLE)$今天宣布,用于治疗精氨酸酶1缺陷(ARG1-D)的pegzilarginase市场授权申请(MAA)已经提交给欧洲药品管理局(EMA)并成功通过验证。该MAA是由Aeglea在欧洲和中东的商业化合作伙伴Imedica Pharma AB提交的。
Pe...查看全文
SeekingBiotech2022-08-19 06:40
AGLE Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency$Aeglea生物制药(AGLE)$查看全文
chuminhua2022-06-03 10:37
6月2日,Aeglea BioTherapeutics 披露,它收到了 FDA 就pegzilarginase 的上市申请的拒绝信(RTF),该申请用于精氨酸酶 1(ARG1)缺乏症的治疗。这一消息导致公司股价下跌多达 44%。
根据 Aeglea 的说法,FDA 要求查看更多数据以支持治疗的有效性,例如有证据表明血浆精氨酸和代谢物减少可预...查看全文
chuminhua2021-12-07 10:32
12月6日,Aeglea BioTherapeutics 周一报告称,pegzilarginase 达到了 III 期 PEACE 试验的主要终点,显着降低了精氨酸酶 1 (ARG1) 缺乏症患者的精氨酸水平。它还透露了在明年上半年寻求 FDA 批准这种新型重组人酶的计划。然而,由于结果低于投资者的预期,公司股价在周一开盘时下跌了近 33%。
查看全文
产业链观察2021-12-06 20:48
药闻▶2021年12月6日,开发新一代人类酶疗法的临床阶段生物技术公司$Aeglea生物制药(AGLE)$ ,今天宣布,关键的3期研究PEACE(Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints)达到了主要终点,在使用pegzilarginase治疗24周后,血浆精氨酸从基线上有了统计学意...查看全文
usbiostock2018-10-01 21:31
$Aeglea BioTherapeutics, Inc.(AGLE)$ FDA授予Pegzilarginase“罕见儿童疾病”认定,用于治疗Arginase 1缺乏症。查看全文
群氓鄙陋2018-09-29 09:33
看来还得关注一下。看看有没有机会//@usbiostock:回复@usbiostock:这周新增了3只股票,$Aeglea BioTherapeutics, Inc.(AGLE)$ $Neon Therapeutics(NTGN)$ $LEAP THERAPEUTICS, INC.(LPTX)$ 在下个月ESMO会议上都有数据更新,看看有没有run。查看全文
$Aeglea BioTherapeutics, Inc.(AGLE)$ 8-K - Current report Filed: 2018-04-12 AccNo: 0001564590-18-008018 Size: 541 KBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Aeglea BioTherapeutics, Inc.(AGLE)$ 8-K - Current report Filed: 2018-03-26 AccNo: 0001564590-18-006714 Size: 34 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers http...
$Aeglea BioTherapeutics, Inc.(AGLE)$ CT ORDER - Confidential treatment order Filed: 2018-03-20 AccNo: 9999999997-18-003308 Size: 10 KB 网页链接
$Aeglea BioTherapeutics, Inc.(AGLE)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2018-03-13 AccNo: 0001564590-18-005405 Size: 290 KB 网页链接
$Aeglea BioTherapeutics, Inc.(AGLE)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2018-03-13 AccNo: 0001564590-18-005404 Size: 11 MB 网页链接
$Aeglea BioTherapeutics, Inc.(AGLE)$ 8-K - Current report Filed: 2018-03-13 AccNo: 0001564590-18-005402 Size: 285 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Aeglea BioTherapeutics, Inc.(AGLE)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2018-03-13 AccNo: 0001564590-18-005405 Size: 290 KB 网页链接
$Aeglea BioTherapeutics, Inc.(AGLE)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2018-03-13 AccNo: 0001564590-18-005404 Size: 11 MB 网页链接
$Aeglea BioTherapeutics, Inc.(AGLE)$ 8-K - Current report Filed: 2018-03-13 AccNo: 0001564590-18-005402 Size: 285 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Aeglea BioTherapeutics, Inc.(AGLE)$ 8-K - Current report Filed: 2018-03-12 AccNo: 0001564590-18-005289 Size: 1 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接